New and emerging treatments for symptomatic tardive dyskinesia

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1329-1340

  Rana, Abdul Qayyum ^a,b,c   Chaudry, Zishan M ^d   Blanchet, Pierre J ^e  

^a Movement Disorders Centre   (Canada)

^b RLS ^*

^c RLS   (Canada)

^d SABA UNIVERSITY SCHOOL OF MEDICINE   (Netherlands)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atypical antipsychotics; First generation antipsychotics; Motor symptoms; Parkinson's; Schizophrenia; Tardive dyskinesia

Indexed keywords

4 [5H 2,3 (2,5 DIMETHYL 2, 5 HEXANO) 5 METHYL 8 NITRODIBENZO [B,E][1,4]DIAZEPIN 11 YL]BENZOIC ACID; AMANTADINE; AMINO ACID DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; BOTULINUM TOXIN; BRANCHED CHAIN AMINO ACID; CARDIOVASCULAR AGENT; CLONAZEPAM; CLOZAPINE; DOCOSAHEXAENOIC ACID; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; ETIRACETAM; FLUPHENAZINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; MELATONIN; MEMANTINE; NEUROLEPTIC AGENT; NUCLEAR RECEPTOR NUR77; PLACEBO; QUETIAPINE; RESERPINE; RESVERATROL; RETINOID X RECEPTOR; SEROTONIN; SEROTONIN ANTAGONIST; TETRABENAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ABSENCE OF SIDE EFFECTS; AKATHISIA; ANTIOXIDANT ACTIVITY; ANXIETY; ANXIETY DISORDER; ATAXIA; BLURRED VISION; BRAIN DEPTH STIMULATION; CHOLINERGIC ACTIVITY; CONSTIPATION; DEPRESSED BLOOD PRESSURE; DEPRESSION; DISEASE ASSOCIATION; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GENE; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; HYPERTHERMIA; MOOD DISORDER; NAUSEA; NERVE CELL PLASTICITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; NONHUMAN; NUR77 GENE; OPEN FIELD BEHAVIOR; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PALLIDOTOMY; PARKINSONISM; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RXR GENE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; SUICIDAL IDEATION; SUICIDE; SUPERSENSITIVITY; SYNAPTIC TRANSMISSION; TARDIVE DYSKINESIA; THALAMOTOMY; VACUOUS CHEWING MOVEMENT;

ATYPICAL ANTIPSYCHOTICS; FIRST-GENERATION ANTIPSYCHOTICS; MOTOR SYMPTOMS; PARKINSON'S; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DRUG DESIGN; DRUG MONITORING; DYSKINESIA, DRUG-INDUCED; HUMANS;

EID: 84887132855     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S32328     Document Type: Review

References (57)

1. Paulsen JS, Heaton RK, Jeste DV. Neuropsychological impairment in tardive dyskinesia. Neuropsychology. 1994;8(2):227-241.
2. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2001;31(1):11-19.
3. Goldberg RJ. Tardive dyskinesia in elderly patients: an update. J Am Med Dir Assoc. 2002;3(3):152-161.
4. Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry. 2007;191:238-245.
5. Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):14-19.
6. Mentzel CL, Tenback DE, Tijssen MA, Visser-Vandewalle VE, van Harten PN. Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia: a systematic review. J Clin Psychiatry. 2012;73(11):1434-1438.
7. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71(4):463-474.
8. Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than Parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53(8): 1374-1379.
9. de Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2007;257(3):169-172.
10. Ragheb MM, Goldberg RJ. Tardive dyskinesia in geriatric patients. Aging Health. 2006;2(5):833-849.
11. Teo JT, Edwards MJ, Bhatia K. Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord. 2012;27(10): 1205-1215.
12. Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics. 2008;9(9):1285-1306.
13. Muller DJ, Chowdhury NI, Zai CC. The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry. 2012;26(2): 144-150.
14. Seeman P. All psychotic roads lead to increased dopamine D2high receptors: a perspective. Clin Schizophr Relat Psychoses. 2008;1(4): 351-355.
15. Ito H, Takano H, Takahashi H, et al. Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? J Neurosci. 2009;29(43): 13730-13734.
16. Seeman P. Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets. 2006;10(4):515-531.
17. Remington G, Kapur S. Antipsychotic dosing: how much but also how often? Schizophr Bull. 2010;36(5):900-903.
18. Ginovart N, Wilson A, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology. 2008;34(3):662-671.
19. Stephenson CM, Bigliani V, Jones HM, et al. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry. 2000;177:408-415.
20. Creed-Carson M, Oraha A, Nobrega JN. Effects of 5-HT2A and 5-HT2C receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res. 2011;219(2):273-279.
21. Grimm JW, Chapman MA, Zahm DS, See RE. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse. 2001;39(1):51-57.
22. Kelley JJ, Roberts RC. Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias. J Neural Transm. 2004;111(8):1075-1091.
23. Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jørgensen HA. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience. 2003;122: 717-725.
24. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2010;33(6):271-275.
25. Ethier I, Kagechika H, Shudo K, Rouillard C, Lévesque D. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry. 2004;56:522-526.
26. Mahmoudi S, Blanchet P, Levesque D. Haloperidol-induced striatal Nur77 expression in a non-human primate model of tardive dyskinesia. Eur J Neurosci. 2013;38(1):2192-2198.
27. Novak G, Gallo A, Zai CC, et al. Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. Psychiatr Genet. 2010;20(1): 39-43.
28. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50(11):703-714.
29. Busanello A, Barbosa N, Peroza L, et al. Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice. Behav Pharmocol. 2011;22(1):71-75.
30. Busanello A, Peroza L, Wagner C, et al. Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol Biochem Behav. 2012;101(2):307-310.
31. van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276-1277.
32. Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2): 507-509.
33. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615-621.
34. Howland RH. Drug therapies for tardive dyskinesia: Part 1. J Psychosoc Nurs Ment Health Serv. 2011;49(6):13-16.
35. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331-373.
36. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-197.
37. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: A practical gabamimetic strategy. Am J Psychiatry. 1990;147(7):445-451.
38. Howland RH. Drug therapies for tardive dyskinesia: Part 2. J Psychosoc Nurs Ment Health Serv. 2011;49(7):17-20.
39. Littrell K, Magill A. The effect of clozapine on preexisting tardive dyskinesia. J Psychosoc Nurs Ment Health Serv. 1993;31(9):14-19.
40. Bassitt DP, Louzã Neto MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 1998;248(4):209-211.
41. Louzã MR, Bassitt DP. Maintenance treatment of severe tardive dyskinesia with clozapine 5 years' follow-up. J Clin Psychopharmacol. 2005;25(2):180-182.
42. Castro F, Carrizo E, Prieto de Rincón D, et al. Effectiveness of melatonin in tardive dyskinesia. Invest Clin. 2011;52(3):252-260.
43. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry. 2000;61(6):556-558.
44. Nelson K, Mcguire J, Hausafus S. Melatonin for the treatment of tardive dyskinesia. Ann Pharmacother. 2003;37(7-8):1128-1131.
45. Lerner V, Miodownik C. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep. 2011;13(4):295-304.
46. Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry. 2006;18(2):133-143.
47. Iwata Y, Irie S, Uchida H, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci. 2012;315(1-2): 137-140.
48. Yamamura S, Ohoyama K, Nagase H, Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology. 2009;57(3):322-331.
49. Lynch B, Lambeng N, Nocka K, et al. The synaptic vesicle protein SVA2 is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861-9866.
50. Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546-554.
51. Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21(8):1219-1221.
52. Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. J Clin Psychiatry. 2004;65(5): 696-701.
53. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160(6):1117-1124.
54. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004;65(1):92-96.
55. Kimiagar I, Dobronevsky E, Prokhorov T, Miniovitz A, Rabey JM. Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study. J Neurol. 2012;259(4):660-664.
56. Thobois S, Poisson A, Damier P. Surgery for tardive dyskinesia. Int Rev Neurobiol. 2011;98:289-296.
57. Welter ML, Grabli D, Vidailhet M. Deep brain stimulation for hyperkinetics disorders: dystonia, tardive dyskinesia, and tics. Curr Opin Neurol. 2010;23(4):420-425.